ly2605541 and Renal-Insufficiency

ly2605541 has been researched along with Renal-Insufficiency* in 1 studies

Trials

1 trial(s) available for ly2605541 and Renal-Insufficiency

ArticleYear
Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
    Clinical pharmacology in drug development, 2016, Volume: 5, Issue:3

    The pharmacokinetics of LY2605541 (basal insulin peglispro), a novel long-acting basal insulin analogue, was evaluated in 5 groups of subjects with varying degrees of renal function based on creatinine clearance: normal renal function (>80 mL/min), mild renal impairment (51-80 mL/min), moderate renal impairment (30-50 mL/min), severe renal impairment (<30 mL/min), or end-stage renal disease (ESRD) requiring hemodialysis. Serial blood samples for pharmacokinetic analyses were collected up to 12 days following a single 0.33 U/kg subcutaneous dose of LY2605541. The apparent clearance (CL/F) and half-life across groups were not affected by renal function. Cmax values were lower in subjects with increasing severity of renal impairment; however, the small decrease in Cmax did not affect the overall exposure. Regression analysis showed that LY2605541 clearance is independent of renal function (slope = 0.000863; P = .885). The mean fraction of LY2605541 eliminated by a single hemodialysis session was 13% in subjects with ESRD. LY2605541 was generally well tolerated in healthy subjects and those with renal impairment following a single 0.33 U/kg subcutaneous dose. Given these data, no dose adjustment of LY2605541 based on pharmacokinetics is recommended in renal impairment or in patients undergoing hemodialysis.

    Topics: Adult; Aged; Female; Half-Life; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Lispro; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Regression Analysis; Renal Dialysis; Renal Insufficiency; Severity of Illness Index

2016